SB1553 amends the Illinois Controlled Substances Act to place xylazine in Schedule III of the state’s controlled substances schedules. The bill also adds xylazine to the criminal penalties framework for unlawful manufacture, delivery, and possession with intent to manufacture or deliver, and it specifically includes xylazine in the felony quantity thresholds used for trafficking-related offenses.
The bill creates a new veterinarian exception stating that the prohibition on delivery or possession with intent to deliver xylazine does not apply to licensed veterinarians who lawfully prescribe, dispense, administer, acquire, or use controlled substances, including xylazine, in the course of professional practice, in good faith, and under generally accepted medical standards. In practical terms, the measure would expand state drug-control enforcement to cover xylazine while preserving legitimate veterinary use.
Impact
The bill would amend Sections 208 and 401 of the Illinois Controlled Substances Act and add new Section 309.1. It would formally classify xylazine as a Schedule III substance, making unauthorized manufacture, delivery, and possession with intent to deliver subject to the Act’s criminal penalties. It also inserts xylazine into the statute’s felony weight thresholds, including Class 1 and Class 2 offense provisions, thereby aligning xylazine with other controlled substances for enforcement and sentencing purposes. Licensed veterinarians would remain exempt when acting within lawful professional practice.
Sentiment
No committee transcripts or recorded votes were provided, so there is no documented floor or committee debate to gauge legislative sentiment. Based on the bill text and caption, the measure appears to be a targeted public-safety and drug-control proposal aimed at restricting illicit distribution of xylazine while preserving legitimate veterinary use. The absence of recorded opposition or amendments in the provided materials suggests no visible controversy in the available record, though that does not indicate unanimous support.
Contention
The main policy issue reflected in the bill is balancing tighter criminal control of xylazine against continued access for veterinarians. Supporters would likely view scheduling as necessary to address misuse and drug-trafficking concerns, especially where xylazine is mixed with other controlled substances. The principal point of contention, if any, would be whether the Schedule III classification and associated penalties could inadvertently burden veterinary practice or legitimate animal-care uses; the bill addresses that concern by creating an explicit professional-practice exemption for licensed veterinarians.